From owner-schistosoma@net.bio.net Mon Mar 01 22:00:00 1999 Path: biosci!biosci!not-for-mail From: Jean-Lou Justine Newsgroups: bionet.organisms.schistosoma Subject: Parasitology Course, 3-5 May 1999, Paris, France Date: 2 Mar 1999 04:51:09 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 207 Sender: daemon@net.bio.net Approved: greveld@uni-duesseldorf.de Distribution: world Message-ID: <7bgmrt$l50@net.bio.net> NNTP-Posting-Host: net.bio.net Message already posted 28/01/99 ------------------------------- Parasitology Course, Paris, France, May 3-5, 1999 "Evolution of Parasites and of Host-Parasite Relationships" Programme of the course at the end of the message and: http://www.mnhn.fr/ens/ed/07-justi.htm List of courses organized in 1999 by the National Museum of Natural History in Paris: http://www.mnhn.fr/ens/ind_ed.htm General information about the National Museum of Natural History in Paris: http://www.mnhn.fr/index.html ---------------- The National Museum of Natural History in Paris, France organizes a series of courses on "Evolution of Parasites and of Host-Parasite Relationships". This course is intended for graduate and post-graduate students and all researchers in the field of parasitology. Registration is free of charge but participants should register in advance. Most of the courses (8/9) will be given in French. Please refer to the following information. The present message also includes the list of conferences, and the form for registration at the end. For more details contact Pr Jean-Lou JUSTINE, e-mail: justine@mnhn.fr ---------------------------------------------------------- "EVOLUTION DES PARASITES ET DES RELATIONS HOTES-PARASITES" May 3-5, 1999 ---------------------------------------------------------- Responsables: Dr Marie-Claude Durette-Desset et Pr Jean-Lou Justine Laboratoire de Biologie Parasitaire, Protistologie, Helminthologie EP1790 CNRS "Biologie et Evolution des Parasites" Museum National d'Histoire Naturelle, 61 rue Buffon, 75231 Paris cedex 05 Tel: (33) 1 40 79 35 03 Fax: (33) 1 40 79 34 99 E-mail: justine@mnhn.fr ---------------------- Informations generales: Programme de ce cours: http://www.mnhn.fr/ens/ed/07-justi.htm Liste des cours organises par le Museum National d'Histoire Naturelle en 1999: http://www.mnhn.fr/ens/ind_ed.htm Site du Museum National d'Histoire Naturelle: http://www.mnhn.fr/index.html Ce cours est organise pour la sixieme annee consecutive. Les cours sont destines a un public tres large de parasitologues debutants ou confirmes. Les personnes assistant aux Conferences peuvent obtenir une "Attestation de Cours" a condition d'assister a la totalite des Conferences et de rediger une courte synthese qui sera jugee par les organisateurs. Il n'y a pas de "resumes" des cours, mais les conferenciers preparent des documents (schemas, textes) qui sont distribues gratuitement aux participants. Une *excellente* connaissance de la langue francaise est necessaire pour assister a ce cours de maniere profitable. En 1999, 8 conferences seront en francais, une en anglais. Malheureusement, rien n'est prevu pour le logement des participants. Les hotels proches du Museum sont relativement chers (250-400 FF) mais il existe des hotels moins chers a Paris. L'inscription au cours est gratuite mais doit etre preferentiellement effectuee a l'avance. Les formulaires sont disponibles sur simple demande. Les cours auront lieu au laboratoire de Chimie, 63 rue Buffon, 75005 Paris. ---------------------------------------------------------- PROGRAMME DU COURS ====================== "EVOLUTION DES PARASITES ET DES RELATIONS HOTES-PARASITES" May 3-5, 1999 ---------------------------------------------------------- Des petites modifications a ce programme sont encore possibles. Lundi 3 mai 1999 10h15-10h30 Accueil des participants 10h30-12h00 Dr Andre THERON (Perpignan) Comportement, rencontre et evolution des systemes Hotes-Parasites 14h00-15h30 Pr Jean-Lou JUSTINE (Paris) Phylogenies des Plathelminthes 15h45-17h15 Dr Tim LITTLEWOOD (Londres) Molecular systematics, phylogenetics and evolution of parasitic Platyhelminthes Mardi 4 mai 1999 10h30-12h00 Dr Gaston PICHON (Bondy) Quantification et modelisation des relations hote/ vecteur/ parasite, principalement appliquees à la filariose de Bancroft et au paludisme 14h00-15h30 Pr Claude VAUCHER (Geneve) Présentation des Cestodes et originalite des cestodoses humaines 15h45-17h15 Dr Anders Pape MOLLER (Paris) Evolution de la virulence: theorie et tests empiriques Mercredi 5 mai 1999 10h30-12h00 Pr Jean-Claude BEAUCOURNU (Rennes) Diversite et strategies d'adaptation des Insectes ectoparasites d'homeothermes 14h00-15h30 Dr Christophe CHARTIER (Niort) Cas particulier des relations hotes-parasites: la resistance des nematodes aux antihelminthiques chez les caprins 15h45-17h15 Dr Marie-Claude DURETTE-DESSET (Montpellier) Rongeurs et Nematodes Trichostrongylina: co-evolution ou capture? Les cours auront lieu dans La Salle de Cours Historique du Laboratoire de Chimie Muséum National d'Histoire Naturelle, 63 rue Buffon 75005 Paris Metro: Gare d'Austerlitz, Jussieu, Censier; Bus: Ligne 89 ---------------------------------------------------------- BULLETIN D'INSCRIPTION ====================== "EVOLUTION DES PARASITES ET DES RELATIONS HOTES-PARASITES" May 3-5, 1999 ---------------------------------------------------------- Responsables: Dr Marie-Claude Durette-Desset et Pr Jean-Lou Justine Laboratoire de Biologie Parasitaire, Protistologie, Helminthologie EP1790 CNRS "Biologie et Evolution des Parasites" Museum National d'Histoire Naturelle, 61 rue Buffon, 75231 Paris cedex 05 Tel: (33) 1 40 79 35 03 Fax: (33) 1 40 79 34 99 E-mail: justine@mnhn.fr ---------------------- Vous pouvez renvoyer ce bulletin d'inscription par e-mail, fax ou courrier. Si vous renvoyez ce bulletin d'inscription par e-mail (methode conseillee): - envoyez-la a l'adresse: justine@mnhn.fr - avec sujet: "bulletin d'inscription rempli" - renvoyez uniquement cette partie, PAS tout le message! NOM: Prénom: Qualité: Etudiant DEA Etudiant Doctorat Annee de These Etablissement d'Inscription Fonction M.E.N. M.E.S.R. C.N.R.S. INSERM AUTRES Adresse professionelle: Adresse personnelle: Telephone: Fax: e-mail (TRES IMPORTANT): Vous pouvez indiquer votre motivation ci-dessous (facultatif). ------------------------------------------------------------------- Prof. Jean-Lou JUSTINE Laboratoire de Biologie parasitaire, Protistologie, Helminthologie CNRS EP 1790 "Biologie et Evolution des Parasites" Museum National d'Histoire Naturelle 61 rue Buffon, 75231 PARIS cedex 05, France Telephone: France 01 40 79 35 03 International + (33 1) 40 79 35 03 Fax: France 01 40 79 34 99 International + (33 1) 40 79 34 99 e-mail: justine@mnhn.fr (Running 'Eudora' on a PPC Macintosh) ------------------------------------------------------------------- GRANTS from PARSYST programme (European Community TMR Programme "Access to Large Scale Facilities" Look at: http://www.mnhn.fr/progsc/index.html Conferences "Evolution of Parasites and Host-Parasite Relationships" Look at: http://www.mnhn.fr/ens/ed/07-justi.htm ------------------------------------------------------------------- From owner-schistosoma@net.bio.net Tue Mar 02 22:00:00 1999 Path: biosci!biosci!not-for-mail From: daemon@net.bio.net Newsgroups: bionet.organisms.schistosoma Subject: Molecular Parasitology Meeting Date: 3 Mar 1999 02:56:43 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 43 Approved: greveld@uni-duesseldorf.de Distribution: world Message-ID: <7bj4hb$qle@net.bio.net> NNTP-Posting-Host: net.bio.net 10th Molecular Parasitology Meeting *********************************** 12-16 September 1999 Woods Hole, MA, USA. Topics to be covered will include molecular biology, cell biology, biochemistry and genetics of protozoan and helminth parasites. Presentations (talks and posters) by graduate students and post-docs are strongly encouraged. Organizers: Christine Clayton (Heidelberg), Kasturi Haldar (Chicago), Buddy Ullman (Portland, Oregon) For information and on-line registration please visit the Web site: http://mpm.mbl.edu/ Alternatively contact Ms. L.-A. King, Marine Biological Laboratory, 7 MBL Street, Woods Hole, MA 02543-1015, USA; lking@hoh.mbl.edu Registration deadline: May 15th 1999 PLEASE NOTE NEW E-MAIL ADDRESS! cclayton@zmbh.uni-heidelberg.de Christine Clayton ZMBH Im Neuenheimer Feld 282 D69120 Heidelberg Germany 49-6221-546876 fax 49-6221-545894 e-mail: cclayton@zmbh.uni-heidelberg.de http://www.zmbh.uni-heidelberg.de -- Sharing news with the t.d.r. community, mailto:tdr-scientists@who.ch To unsubscribe, or subscribe, write to: owner-tdr-scientists@who.ch Ref: "Networking for t.d.r." http://www.who.int/tdr/kh/res_link.html From owner-schistosoma@net.bio.net Thu Mar 04 22:00:00 1999 Path: biosci!biosci!not-for-mail From: "K.R.Hata" Newsgroups: bionet.organisms.schistosoma Subject: Dr Brundtland's speech at TDR's STAC Date: 5 Mar 1999 02:32:19 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 269 Sender: daemon@net.bio.net Approved: greveld@uni-duesseldorf.de Distribution: world Message-ID: <7bobrj$ljd@net.bio.net> NNTP-Posting-Host: net.bio.net Dear TDR-scientists, Let me share with you a speech of Dr Brundtland at the opening of TDR's STAC meeting this week. It has just appeared at WHO's Web page. [http://www.who.int/inf-dg/speeches/english/hq_01031999.html] Bob Hata Host of tdr-scientists list -- Dr Brundtland's speech at TDR's STAC ************************************ Dr. Gro Harlem Brundtland Director-General World Health Organization WHO Headquarters, 1 March 1999 21st Meeting of the Scientific and Technical Advisory Committee of the Special Programme for Research and Training in Tropical Diseases Dear Members of the Scientific and Technical Advisory Committee, It is a pleasure for me to welcome you to WHO at a time which combines continuity and change. Continuity, because so much of what WHO has been doing for the health of so many is worth while pursuing. TDR is a prime example of this. It is an example of world class expertise. It is an example of what the best of partnerships can bring to the advancement of technology, medicines and alleviation of suffering. Change because the world around us is changing and because WHO as an Organization needs to reposition itself to make a real difference for global health. We are changing to better focus our work, to get better synergies between related activities, to forge closer relations with our Member States, to devise more effective partnerships with others. We are changing to better cope with a mandate which Member States tend to increase, whereas the resources remain restricted. We are changing because any organization needs to constantly work to become better -- more effective -- more passionate. Among your documents you will find a description of our new structure, based on clusters. We have grouped the previous individual programmes into nine clusters -- and then we have turned what used to be more than 50 programmes into 32 departments. TDR is located at the heart of the Communicable Diseases Cluster. The mission of the cluster is as simple as it is daunting: to reduce the impact of communicable diseases worldwide by leading the global effort in prevention, control, surveillance and research. Its mandate is broad, ranging from monitoring the emergence of new, sometimes unknown, diseases to the possible eradication of those against which we have efficient tools and strategies. It is a major challenge. Communicable diseases remain the most common cause of death in the world. Of the 52 million deaths worldwide per year, an estimated one-third are due to infectious diseases. And we have all the evidence to say that the main burden of communicable disease is carried by the poor. WHO -- committed to the cause of equity and the fight against poverty -- has to maintain the fight against communicable diseases as a key priority. Of particular concern to us are the tropical diseases. Some call these indigent diseases as they mainly affect the poor and do not get the attention they deserve. Our ambition is to do what we can to change that. The 24-year history of TDR tells the story of how three international agencies, the World Bank, the United Nations Development Programme, and WHO, jointly with other loyal partners, have worked together to improve the health of those affected by tropical diseases. TDR is rightly regarded as one of WHO's success stories. You are a major player in that story. As TDR's highest scientific committee, you have had a crucial role in keeping the programme alive and dynamic, setting and updating its priorities and direction. TDR is indeed a special programme. Twenty-four years is no age. It is still active and forward-looking, very relevant and, in fact, crucial, to meet the challenges posed by tropical diseases. All of these qualities will be needed, because there are major tasks ahead. Let us first review the current setting: * WHO's reorganization has created an atmosphere that favours change, and we are fully committed to promote changes that will make a difference where it matters - the health conditions of disease endemic countries. Let us take advantage of this change process to strengthen the impact of our efforts also in TDR's area. * TDR has undergone its 3rd External Review, which made suggestions on how to make this successful Programme even better. At the request of its Joint Coordinating Board, TDR is working on a new Strategic Plan with a long-term vision to guide the Programme in the next years, incorporating the suggestions of the External Review. As you know, TDR has two basic goals: 1. Promote R & D for the development of new and improved tools to control tropical diseases. 2. Build research capacity of developing endemic countries through training and institutional strengthening. Research and training for disease control - a simple, clear and relevant mandate, is as needed and as valid today as it was 24 years ago. We desperately need new and better tools, tools that are effective, appropriate and affordable, and we desperately need to increase the scientific capacity of the countries that suffer the toll of tropical diseases. Let me give you some examples. You know I have selected malaria and tuberculosis as priorities among the communicable diseases. Since July we have launched the Roll Back Malaria project and the Stop TB Initiative. * In relation to malaria, our target is to halve its burden through interventions adapted to local needs, and reinforcement of the health sector of the affected countries. This is a formidable task which will require concentrated efforts to radically improve the health systems of the poorest countries on earth - and to cope with the problem of increasing resistance to the available drugs. * The situation is also very serious with regard to the spread of tuberculosis. Drug resistance is spreading, some countries are facing problems in relation to the implementation of the DOTS strategy, and the association of tuberculosis with HIV/AIDS is cause of great concern. We could dramatically change the pattern if new tools became available. For example, recent studies show us the impact new effective tools could have on tuberculosis by the year 2030: * a new vaccine with 50% efficacy could lower tuberculosis incidence by 36 million cases and mortality by 9 million deaths; * a single-contact treatment could avert 24 million cases and 11 million deaths; * active case finding by using mass miniature radiography could save 23 million lives And let us at this stage only leave to our imagination the far-reaching consequences of a good malaria vaccine. All our knowledge is about the past -- but all our challenges lie in the future. This is what stimulates researchers and scientists to make an extra effort. So let us look briefly into that future. We are again facing an old dilemma: Should we invest in dreams, such as a malaria vaccine, or should we concentrate our resources on better use of existing tools? I want to reiterate once more: Research is essential. Decades ago a polio vaccine was also just a dream, and the debate was raging between those idealists who fought for it and those who wanted better iron lungs and rocking beds to alleviate the intense suffering of polio victims. As we approach polio eradication - made possible by the development of effective oral vaccines - we forget how difficult the decision was to keep investing in a dream that no one knew could become a reality. Let us keep some of the dreams alive. We definitely need new knowledge to fight tropical diseases. We need to know our enemies better. These are: * The pathogens that cause the diseases; * The vectors that transmit them; * The factors that undermine our defences against infection; and * The environmental, social, economic and behavioural determinants that help disease propagation. New knowledge, however, is not enough - we have to transform that knowledge into tools for disease control. We need: * new and improved drugs, vaccines and diagnostics that can be afforded by the poor; * new and improved interventions, suitable for adoption by the health systems of poor countries; * better methods for vector control that do not further exacerbate the environmental situation of our planet. TDR will be 25 years old next year as we enter a new century -- a new millennium. We will commemorate this Jubilee not only with festivities. We will demand that TDR assume new duties, tasks, challenges and responsibilities. To be very direct -- to assume more hard work. TDR's new Strategic Plan, which will guide its future path, will be presented in full to the Joint Coordinating Board this June. It will focus on these new challenges and work with us in developing approaches to undertake them. I count on you to carefully analyse the options presented in the draft plan, discuss their implications and help TDR to make the right choices. Among the options we are proposing is to expand TDR's disease portfolio to include tuberculosis and dengue. During this meeting, you will be presented with the reasons why we think TDR must expand its mandate to include these two infectious diseases. To me it is clear; carefully expanding the mandate means living up to TDR's achievements. Carefully expanding the mandate means strengthening our ability to make a difference. We also need your help with another matter. Before I took office, I met with the group of outside experts that conducted the Third External Review. They told me that TDR has worked hard and effectively to accomplish its mandate. And I know that it has done so using only catalytic resources, or seed money. TDR could do better, and more, if we could mobilise additional funds. I am fully committed to do what I can to make this happen. In the long run I can think of few more cost-effective investments in health. * I do so when I ask our Member States not to adopt a budget which decreases our resources and pulls towards a downsizing of WHO and limited ability to deliver the work that the same Member States expect us to do. * I will do so as we continue to raise money in the belief that WHO can merit a larger share of the voluntary contributions Member States and others are willing to commit to health and development. * I will do so when I will continue our achievements of the last 8 months and further rationalise the way we operate at Headquarters, Regional and country levels, to save precious resources and to redirect even more funds from administrative areas to our technical work. Getting more funds and renewed support from Member States, donors and other partners is of course our task - but you do have a share in the effort and responsibility. Your sound advice is crucial to TDR and the Communicable Diseases cluster - and therefore to WHO. We are partners committed to better world health. Your work, as TDR's top scientific experts, will impact on the Programme's performance and that of WHO. I am looking forward to receiving your advice. I wish you success in your deliberations, and I wish TDR a bright future, as it approaches its 25 years of existence and as it looks ahead to new challenges and opportunities into a new century. Thank you. -- Sharing news with the t.d.r. community, mailto:tdr-scientists@who.ch To unsubscribe, or subscribe, write to: owner-tdr-scientists@who.ch Ref: "Networking for t.d.r." http://www.who.int/tdr/kh/res_link.html From owner-schistosoma@net.bio.net Thu Mar 04 22:00:00 1999 Path: biosci!biosci!not-for-mail From: rollin@writeme.com Newsgroups: bionet.organisms.schistosoma Subject: ISAAST '99 Date: 5 Mar 1999 01:04:09 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 48 Sender: daemon@net.bio.net Approved: greveld@uni-duesseldorf.de Distribution: world Message-ID: <7bo6m9$dmk@net.bio.net> NNTP-Posting-Host: net.bio.net September 8-12, 1999 Beijing, China Scientific Sessions 1. Biological Science 2. Clinical & Experimental Medicine 3. Health Care for the Elderly 4. Traditional Chinese Medicine in Aging & Antiaging Exhibition The companies engaged in producing the instruments or reagents that may facilitate the antiaging researches are welcomed and encouraged to exhibit their high-tech products. For whose interested in the exhibition, please contact us at your earliest convenience. Sponsor Antiaging Science & Technology Society£¬ Gerontological Society of China Organizers Antiaging Science & Technology Society , Gerontological Society of China China International Symposium Center for Sciences and Technology (CICCST) Co-Organizer BILONG Institute for Transgenic Animals in Beijing (BITAB) Supporters Gerontological Society of China Institute of Medicinal Biotechnology, Peking Union Medical College, Chinese Academy of medical Sciences Beijing Hospital and Gerontological Research Institute (to be continued) Contact: ********************************************************* BILONG Academic Events Add: 8 Nan Er Jie, Zhong Guan Cun, Beijing 100080, China Box: P.O. Box 8734, Beijing 100080, China Tel: 86-10-6256-0561, 6256-2226 Ext 211, 800-810-0797 Fax: 86-10-6253-2114 Email: BAE@bilong.com ********************************************************* From owner-schistosoma@net.bio.net Mon Mar 15 22:00:00 1999 Path: biosci!biosci!not-for-mail From: VIAL Henri Symposium Newsgroups: bionet.organisms.schistosoma Subject: Symposium DRUGS AGAINST PARASITIC DISEASES, Montpellier, 2nd call Date: 16 Mar 1999 04:50:11 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 398 Sender: daemon@net.bio.net Approved: greveld@uni-duesseldorf.de Distribution: world Message-ID: <7clk23$7lj@net.bio.net> NNTP-Posting-Host: net.bio.net EUROPEAN UNION - DG XII, Cooperation with Third Countries INCO-DC program COSTB9 , European Cooperation in the Field of Scientific and Technical Research WORLD HEALTH ORGANISATION, Tropical Disease Research Programme This is the second announcement (15/03/99) for an international symposium on ------------------------------------------------------------- DRUGS AGAINST PARASITIC DISEASES 24th to 26th May 1999, Montpellier, France ------------------------------------------------------------- Practical information : http://162.38.196.39/drug-symposium symposia@univ-montp2.fr Henri VIAL/ Christine BOUSQUET UMR 5539 CNRS/Université Montpellier II, cc107 Place Eugène Bataillon 34095 Montpellier cédex 5, France Tél. : (33) 4.67.14.42.87 Fax. : (33) 4.67.14.42.86 ------------------------------------------------------------- SCOPE OF THE MEETING The meeting is being organized under the auspices of the European Commission INCO-DC program, by the Tropical Diseases Research Branch of the World Health rganisation and as the annual spring meeting of the European Concerted Action on hemotherapy of Protozoal Infections (Cost action B9). The symposium should offer pportunities for future collaborations and discussions between these Institutions in such n important area. >This meeting will provide experts in Parasitology, Biochemistry, cellular and molcular Biology, Chemistry, Pharmacology, Toxicology, and research managers with a forum in which to discuss advances and up-date their knowledge concerning drug discovery in the area of parasitic diseases and to provide facilities to accelerate drug evelopment in this crucial field, and ways of improving control strategies. In addition, new research tools are available such as genomics, genetic manipulaton. These represent opportunities from basic research to the definition of operationa research. Particularly, how to capitalise on information on the whole genome approache of the parasite. What is the optimal utilisation of this information ? Which of this biocheical pathways of these organisms can be used for future drug development ? We have invited prominent scientists and experts to present data on up-to-date topics and would gladly welcome short communications or posters you might have on the various topcs. We hope hat this conference will strengthen the collaboration between scientists, experts, an professionals both in the North and the South, thus promoting excellence not only in resarch but also in practical implementation. ------------------------------------------------------------ SCIENTIFC COMMITTEE Croft, (London, UK) Hagan (Glasgow, UK) Horton (London, UK) Kharazmi (Copenhagen, Denmark) Lanzer (Heidelberg, D) Perie (Toulouse, F)( Local Organizer) Olliaro (Geneva, CH) Opperdoes (Louvain, B) Ridley (Geneva, CH) Traore (INCO-DC, Brussels, and Mali) Vial (Montpellier, F) (Local Organizer, Coordinator) ------------------------------------------------------------ RELIMINARY SCIENTIFIC PROGRAMME (15/03/99) OPENING: GLOBAL PICTURE OF ANTIPARASITIC DRUGS AND NEED IN CNTROL STRATEGIES Rob Ridley (WHO, Geneva, CH) : Parasitic disease: the need for new approaches to tropical disease drug discovery and development for improved control strategies. Patrice Trouiller (Grenoble, F) : Drug development output for tropical diseases : what ae the economic constraints ? >>SESSION I: HOW TO DISCOVER NOVEL PHARMACOLOGICAL TARGETS: THE PRASITE >>GENOMES, WHAT DO THEY PROMISE AND WHAT ARE THE LMITATIONS ? >>- Alister Craig (Oxford, UK) : The international programme on P. >>falciparum genome squencing; status and Post-Genomic Agenda. > Sara Melville, (Cambridge, UK) : Organisation of the T. brucei genome > David Parry Smith (Cambridge, UK) : Overview of Bioinformatics and >Applications in Dug Discovery >-Pierre Casellas (SANOFI , Montpellier, F) : DNA chips: applications in >pharmacology >-Chris Gray (Hofmann La Roche, Basel, CH) : Bacterial Targets and >Antibiotics: Gnome-Based Drug Discovery (Proteomics and application to >pathogens). >-Daniel Lawson (Sanger Center, Cambridge, UK) : Mechanistics of >Bioinformartics. >-xxx : Use of genetic engineering for demonstrating potential for Efficacy. >>SESSION II: COMPOUNDS ACQUISITION AND SEQUENTIAL STEPS FROM THE BNCH TO >>THE THRESHOLD OF PRECLINICAL STUDIES OR RATIONAL FOR DRUG DVELOPMENT >>- J. Martinez (CNRS, Montpellier, F): Combinatorial chemistry: a new >>challenge in dug discovery > xxx Natural sources. Search for potential antimalarial from natural >sources (plants). Ehnopharmacology , bioassay guided fractionation and >structure elucidation. > A. Fairlamb, (Dundee, Scotland) : Trypanothione reductase and >validation of this pathway as drug target by producing knock outs in >leishmania. > Micheal H. Gelb, (Seattle, USA) Protein Prenylation in Trypanosomatids: >A New "Piggy-Back" Medicinal Chemistry Target for Drug Development > Paul Michels (Louvain, Belgium) : On the mathematical modelling of >metabolic pathways and its use in the identification of the most suitable >drug targets. (he has acepted) > P. Olliaro (WHO, Geneva) Rationale and Criteria for Drug combination. >>SESSION III : METHODS FOR SCREENING OF POTENTIAL DRUGS. EVALUATION O >>PHARMACOLOGICAL ACTIVITIES. >>- Simon Croft, (London, UK) In vitro and in vivo models for antiprotozoal >>activity - prpose and relevance >- Alan Thomas (BPRC, Rijswijk, NL) : Models for the in vivo testing of >potential compounds against malaria. >- J Julio Martin (Glaxo Wellcome, Madrid, Spain) : Screening methodologies >for chemotherapeutic targets. High throughput screening as an essential >complement to the genomic approach. Advanced technology to assist high >throughput screening >- Pascal Ringwald, (IRD, Yaoundé, Cameroon) : In vitro and in vivo >chemosensitivity testing of the malaria parasites (where, who, how ...). >Worlwide dynamic of resistance. >- Pradipsinh Rathod, (University, Washington, USA) : Induction of >resistance: when to ask this question and how to get an answer ? > >SESSION IV: PRE-DEVELOPMENT WORK: HOW TO GO THROUGH THE CLINICAL STAGES. > >- Thomas Wellems (Bethesda, USA) : The molecular basis of chloroquine >resistance >- Hagai Ginsburg (Hebrew University of Jerusalem) : Targets for malaria >drug development derived from basic research >- Robert G. Ridley (WHO/TDR, Geneva, CH) : Developmental compounds in the >pipeline for treatment and/or prophylaxis of malaria. >- Deborah Kioy (WHO, Geneva, CH) : Essential toxicological and >pharmacokinetic data needed before preclinical studies >- John Horton (SKB, London, UK) Various steps from preclinical phase to >the clinical trials and marketing. > >SESSION V: ECONOMIC CONSIDERATIONS CONCERNING ANTIPARASITIC DRUGS >- Pascal MILLET, (Bordeaux, F) : How to create a link between fundamental >research and the pharmaceutical industry in Tropical Medicine? >- M. Traore (Mali, and INCO-DC, EU, Brussels, B) or Y. Yuthavong (Bangkok, >Thailand) : Role of endemic countries in research and development. >- Win Gutteridge (WHO/TDR, World bank, Geneva, CH) : The New Medicines >for Malaria Venture (MMV) >- Palle Hoy Jakobsen (Denmark) : Patent policy and strategies for >tropical diseases: who and in which countries >- John Horton (SKB, London, UK) : Private sector: defect of the industrial >partner or lack of good compound. > >------------------------------------------------------------- >LOCATION: > >The Symposium will be held at " LE CORUM ", Conference and Culture Centre >in the heart of Montpellier, easily accessible from the "Montpellier >Méditerranée" Airport, and the TGV high speed train station. >Montpellier is Situated in the South of France, only a few miles from the >Mediterranean Sea, Montpellier is the capital of the Languedoc-Roussillon >Region. >The international Montpellier-Mediterranée Airport is served by several >international companies, including Air-France, British-Airways and >Air-Littoral. Around 20 connecting flights with Paris are organised by >three different companies. A regular bus service links the airport to the >city centre. >The High Speed Train (TGV) links in four hours and several times per day >Montpellier with Paris. The TGV Railway Station is only five minutes >walking distance from the "Corum" Conference and Cultural Centre. > >The A9 motorway passes by Montpellier. The easiest exit to reach the Corum >Conference and Cultural Centre is "Montpellier-Est". Cars can be parked in >the "Corum" Centre basement parking (Charge). >------------------------------------------------------------- >PRACTICAL INFORMATION > >The full text of the second announcement, including the electronic form >for congress registration and lodging reservation form is available on our >Web site at the following address : http ://162.38.196.39/drug-symposium/. >Participants are encouraged to use electronic registration and >accommodation form for lodging. >For Hotel reservations : May 1st 1999 (See below) >We invite you to register your travel arrangement and reserve your hotel >as soon a possible. Indeed, the internal and, may be, international >flights, may be overcrowded on this week end, as will be the hotels. > >------------------------------------------------------------- >ORAL OR POSTER CONTRIBUTIONS: DEADLINES AND INSTRUCTIONS FOR THE >PREPARATION OF ABSTRACTS > >Participants wishing to present a contribution should submit an abstract >following the format detailed below, not later than 26 March 1999 (oral >contribution), or 15 April (poster contribution), to the address indicated >above (secretariat of the conference). >Full one-page abstracts will be reproduced directly from the authors' >original documents. These should be typed using A4 formatted paper with >the following format: Title (in bold), Author's names (NAME, I.N. in >roman), Author's affiliation (in italic), body text (one column) They >should have a length of approximately 400 words including title and >eventual references. The name of the person presenting the paper should be >underlined. Eventual references should be indicated within brackets in the >text and listed at the bottom of the abstract. Abstracts should be >submitted by e-mail (as attached file) to the following address: >symposia@univ-montp2.fr, or failing that, on diskette (PC is >preferred)(rtf file is the most appropriate), accompanied by two copies of >the printed version, to the conference secretariat. >Accepted papers for oral and poster contributions will be included in the >conference programme and the book of abstracts only after receipt of the >registration fees. However, the inclusion of presentation as an oral >communication will be dependent on the final scientific programme, as >numbers will be limited. You will be informed of our decision before >April 26th. If not included as an oral communication, you will be invited >to present your paper as a poster. The abstract book including all >lectures and oral and poster contributions will be handed out to the >registered participants upon arrival. > >------------------------------------------------------------- >REGISTRATION/ PAYMENTS > >The registration fees covers the following items : >1. Participation in the Scientific Programme >2. Conference material >3. Volume of abstracts >4. 3 lunches + 1 cocktail >5. Coffee breaks >The banquet is not included in the registration fees. >All bank charges must be paid by the participant and your signature is >essential for your registration. > >DEADLINES : >Your registration will take effect from the moment when the payment >arrives at our office. Accepted papers for oral and poster contributions >will be included in the conference programme only after receipt of the >registration fees. Registration will be confirmed if payment is received >at the conference office by 30.04.1999. If your registration cannot arrive >by 30.04.1999, you should register at the conference Office immediately >after your arrival. > >------------------------------------------------------------- >REGISTRATION FORM (CUT HERE) > >I hereby register for participation in the the Symposium DRUGS AGAINST >PARASITIC DISEASES > >TITLE (Dr, Mr, Ms etc.).... SURNAME....................FIRST >NAME...................... >INSTITUTION/COMPAGNY........................................................... >........ >ADDRESS........................................................................ >........ >............................................................................... >........ > >TEL............................ FAX.......................... >E-MAIL.................................................................. > >I intend to present a paper/poster entitled : >............................................................................... >.......... >............................................................................... >.......... >......................................... >at session: ............................................................... > >Registration...................Before 15/04/1999..............After 15/04/1999 >Regular participant ...........1.200 FF or 213 US$............1.500 FF or >266 US$ >CNRS participant...............1.000 FF.......................1.200 FF >*Participation at the banquet .........350 FF or 62$ >(optional) >TOTAL >AMOUNT................................................................... > >HAS BEEN PAID THIS DAY BY / >Bank transfer : Please indicate your name and the title of the symposium, >domiciliation : tpmontpellier trésorerie générale - code banque : 10071 - >code guichet : 34000 - n° de compte : 00003003417 - clé RIB : 66. >or >Purchase order or Bank cheque in Francs or Dollars, made out to "Agent >Comptable du CNRS ". >Please write on your registration form the total amount (conference fees, >and eventually banquet). > >Signature: > >Please fill in and return the enclosed registration form as soon as >possible. All registrations, cancellations and alterations should be sent >to : > >Conference Secretariat: >Mme Christine BOUSQUET >UMR 5539 CNRS/Université Montpellier II, cc107 >Place Eugène Bataillon >34095 Montpellier cédex 5 >Tél. : (33) 4.67.14.42.87 Fax. : (33) 4.67.14.42.86 >E.Mail : symposia@univ-montp2.fr >http://162.38.196.39/drug-symposium/. > >------------------------------------------------------------------------------- >---- >HOTEL ACCOMMODATION >DIRECTLY BY « LE CORUM » > >All participants have to fill in the attached form and send directly to « >Le Corum » who will arrange reservations in hotels. We invite you to >register your travel arrangement and reserve your hotel as soon a >possible. Indeed, the internal and, may be, international flights, may be >overcrowded on this week end, as will be the hotels. > >------------------------------------------------------------------------------- >---- >ACCOMODATION FORM (CUT HERE) >DRUGS AGAINST PARASITIC DISEASES >MAY 24/26, 99 > >FILL IN ONE REGISTRATION FORM PER PARTICIPANT IN CAPITAL LETTERS >-SEND IT BACK WITH THE PAYMENT ENCLOSED BEFORE MAY 1st, TO : > >STE LE CORUM - SERVICE CONGRES - BP 2200 - Esplanade Charles de Gaulle - >34027 MONTPELLIER CEDEX1 - FRANCE >Tel : 33 (0) 4 67 61 67 61/ Fax : 33 (0) 67 61 66 84 >e.mail : corum@gestion-montpellier.fr > >Mr Mrs Drr Pr > > >FAMILY NAME FIRST NAME > > >ADRESS > > > > >ZIP CODE CITY > > > >COUNTRY > > >PHONE FAX > > >PLEASE RESERVE A HOTEL : 4 H 3 H Chain 3 Tradition H > 2 H > or second choice > > >.....room(s) for ......person(s) Single Double > twin beds > > >I will arrive at Montpellier on May ......... and will leave on >May.......... > >ACCOMMODATION FEE >CLASS PRICE MINI-PRICE MAXI DEPOSIT AMOUNT >4 H 625 FF - 700 FF 565 FF x.......... >3 H Chain 480 FF - 600 FF 465 FF x.......... >3 H Tradition 380 FF - 500 FF 365 FF x........... >2 H 300 FF - 400 FF 265 FF x........... >Tourist tax not included > >The table above indicates the approximate price for each room per night, >with breakfast,V.A.T and service included (valid until December 31, 1999 >subject to change without notice >For accommodation, the deposit amount includes 65 FF for processing.(i.e : >Amount ex-VAT : 53,90 FF / VAT 20,60% 11,10 FF) >Only applications received with payment enclosed will be considered. >Accommodation forms received after May 1st, upon availability only. >CANCELLATION : Deposits will be refunded only upon written cancellation >addressed to LE CORUM (letter, fax or E.Mail) at least 15 working days >before the beginning of the Congress. A fee of FF 65 (taxes included) will >be deduced for processing > >PAYMENTS BY CHECKS : Please make your check payable to CORUM / HEBERGEMENT > >PAYMENTS BY SWIFT TRANSFER :.Code Swift : BWOR - FRPP. >CORUM / HEBERGEMENT - N° 08 401 57 894 N - Banque WORMS, 8 Bd Ledru >Rollin, 34000 MONTPELLIER. - FRANCE >PLEASE INFORM YOUR BANK THAT THE TRANSFER FEES MUST BE PAID BY THE ISSUER. > >PAYMENT: CHECK SWIFT TRANSFER > >THE FORM SENT BY INTERNET DOES NOT REPRESENT A HOTEL RESERVATION. >ONLY THE FORMS SENT BY MAIL WITH THE PAYMENT ENCLOSED WILL BE PROCESSED. >DATE SIGNATURE : > > > > >Symposia@univ-montp2.fr >http://162.38.196.39/drug-symposium >Henri VIAL/ Christine BOUSQUET >UMR 5539 CNRS/Université Montpellier II, cc107 >Place Eugène Bataillon >34095 Montpellier cédex 5, France >Tél. : (33) 4.67.14.42.87 Fax. : (33) 4.67.14.42.86 >personal e-mail: vial@univ-montp2.fr > From owner-schistosoma@net.bio.net Mon Mar 15 22:00:00 1999 Path: biosci!biosci!not-for-mail From: Hooman Momen Newsgroups: bionet.organisms.schistosoma Subject: tdr Meegid-4 Date: 16 Mar 1999 01:14:18 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 83 Sender: daemon@net.bio.net Approved: greveld@uni-duesseldorf.de Distribution: world Message-ID: <7cl7da$kec@net.bio.net> NNTP-Posting-Host: net.bio.net ----------------------------------------------------------------------- -posted for tropical disease research community: "tdr-scientists list" ----------------------------------------------------------------------- The Fourth International Meeting on Molecular Epidemiology and Evolutionary Genetics of Infectious Diseases, will be held at Dakar, Senegal, June 21-24,1999. The three objective of these meetings are: First, to integrate epidemiologic, molecular biologic, and evolutionary genetics approaches in areas of diagnosis, strain typing, species identification, pathogenesis, antigenic variation, drug and vaccine resistance, and host and vector specificity. Second, to foster interactions between epidemiologists and laboratory scientists working on parasites, yeast and fungi, bacteria, and viruses. Third, to provide health care providers, public health professionals, policy makers, epidemiologists and laboratory scientists, and program managers an opportunity to discuss the use of the genetic tools and methodologies that are needed to meet the challenges of diagnosis and management of emerging, re-emerging, and endemic infectious diseases. Submission of abstracts: Abstracts should be about 250 words. Abstracts must be received by March 31, 1999 and should be accompanied by the registration fee Abstracts can be sent as an e-mail attachment or by diskette. The proceedings of the meeting will be published in the Journal of Microbiological Methods. Abstracts and registration fees should be sent to Michel Tibayrenc, Centre d'Etudes sur le Polymorphisme des Microorganismes, IRD, BP 5045, 34032 Montpellier Cedex 1, France. Phone 33 4 67 41 61 97 Fax 33 4 67 41 62 99 Email Michel.Tibayrenc@cepm.mpl.orstom.fr Further information about the meeting can be obtained at the web site for the event: http://cepm.mpl.orstom.fr/ <><><><><><><><><><><><><><><><><><> Hooman Momen Ph. D. Instituto Oswaldo Cruz, FIOCRUZ Av. Brasil 4365, Rio de Janeiro 21045-900, Brazil email: hmomen@gene.dbbm.fiocruz.br Chief, Department of Biochemistry and Molecular Biology Fax: (+55-21)- 590-3495 Tel: (+55-21)- 598-4348 or 290-7549/or 7459/or 7071 Ext./Ramal 147 Editor, Memorias do Instituto Oswaldo Cruz Fax: (+55-21)- 280-5048 Tel: (+55-21)- 598-4335 <><><><><><><><><><><><><><><><><><> Dr.Christoph G.Grevelding Genetic Parasitology Institute of Genetic & Center for Biological and Medical Research Heinrich-Heine-Universitaet Universitaetsstrasse 1 40225 Duesseldorf Tel.:(49)-211-81-13070 Fax :(49)-211-81-12333 (49)-211-81-12279 e-mail: Christoph.Grevelding@uni-duesseldorf.de http://www.uni-duesseldorf.de/WWW/MathNat/Parasitologie/gen_para.htm From owner-schistosoma@net.bio.net Thu Mar 18 22:00:00 1999 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.organisms.schistosoma Subject: BIOSCI/bionet miniFAQ & Fundraiser Date: 19 Mar 1999 03:09:30 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 235 Sender: daemon@net.bio.net Approved: greveld@uni-duesseldorf.de Distribution: world Message-ID: <7ctb9a$835@net.bio.net> NNTP-Posting-Host: net.bio.net >(LAST REVISION: 30-JUL-95) > >This BIOSCI "miniFAQ" is designed to answer the questions that come up >the *most frequently*. The main BIOSCI FAQ (Frequently Asked >Questions) is accessible on the World Wide Web at URL >http://www.bio.net/. > >If you can not find an answer to your question in this or other >documentation, the BIOSCI technical support staff answers e-mail >queries sent to > > biosci-help@net.bio.net > >We can only answer questions about the use of the newsgroups and >mailing lists. We unfortunately do not have the staff to do Internet >information searches or answer scientific questions. Please post >those to the appropriate BIOSCI/bionet newsgroups. > > > Contents: > -------- > 0) BIOSCI NEEDS YOUR SUPPORT!! > > 1) Using the WWW to access the BIOSCI/bionet newsgroups. > > 2) What to do about "spams," i.e., junk mail, ads, etc. > > 3) Examples of subscribing and unsubscribing to the mailing lists. > > 4) The BIOSCI user address and research interest directory. > > >0) BIOSCI NEEDS YOUR SUPPORT!! >------------------------------ >BIOSCI's government funding has been expended, and we are now >operating solely from advertising revenue that we have raised from our >Web site at http://www.bio.net/. We need just a few minutes of your >time to help us serve you. > >You can do two important things which will take very little time for >you individually and will immensely help us continue to help you. > >First, please use our WWW system at http://www.bio.net/ to access the >archives. You can post or reply to messages via your Web browser as >described in item #1 below. Your usage helps attract sponsors. If you >contact any of our sponsors, please be sure to thank them for >supporting BIOSCI. It is critical for them to get this feedback if >they are to continue their sponsorship for the long term. > >Second, if you work for a company or organization that provides >products or services of interest to the biology community, please pass >this message on to your marketing or marketing communications >department or other appropriate group. Please ask them to help >support BIOSCI by sponsoring our Web site and explain the uses and >benefits of the system to the biology community. If they are >interested, they can then contact us for further information at our >tech support address, biosci-help@net.bio.net. > > >1) Using the WWW to access the BIOSCI/bionet newsgroups. >-------------------------------------------------------- >As of 10 December 1995, all BIOSCI/bionet full newsgroups are >accessible through the World Wide Web (WWW) at URL http://www.bio.net. >One can read and reply publicly or privately to both recent postings >and archived messages through one's Web browser if it is configured >properly to send e-mail. Each newsgroup is equipped with its own WAIS >index. The main BIOSCI home page also has access to the BIO-JOURNALS >Table of Contents database WAIS index and the BIOSCI user address >database described in another item further below. > > >2) What to do about "spams," i.e., junk mail, ads, etc. >------------------------------------------------------- >BIOSCI is a set of parallel USENET newsgroups (the "bionet" groups), >mailing lists, and a hypermail archive at URL http://www.bio.net/. >The same postings are distributed on all media (except for a small >number of mailing-list-only groups at net.bio.net). Unfortunately it >is becoming a despicable practice on the Internet (by a few people out >to make a fast buck) to do automated mass postings to thousands of >newsgroups and mailing lists. These attempts to grab free advertising >are refered to as "spams" in the usual, somewhat boneheaded, net >terminology. USENET is more susceptible to this practice, and many >spams originate on the USENET groups and then are passed on to the >mailing lists. However, spammers also get lists of mailing addresses >and hit these too, so neither medium is immune. > >What should you do personally if you get junk mail? >--------------------------------------------------- >Just delete it and move on without reading it further. Filing a >protest is becoming increasingly useless because spammers are often >disguising the addresses where the messages are sent from. Unless you >really understand Internet mail systems, your attempt at protest by >sending replies to the message will often end up being sent to the >address of an innocent person that the spammer is victimizing. > >What can BIOSCI/bionet do to protect its newsgroups? >---------------------------------------------------- >The only solution currently available is to moderate the newsgroup. >If this newsgroup is already moderated, then you are in good shape. >Moderation protects the USENET distribution from about 95% of the >spams that are being sent to date and protects the mailing lists >completely. Moderation means, however, that someone has to take the >time to review each message before it goes out. We have set up >software here that simply allows the moderator to forward to an >address at net.bio.net messages that (s)he wishes to have distributed. >This takes no more time than that needed to read the message and pass >it on, say about 1 min. per message. > >Most newsgroups currently have a discussion leader who is responsible >for their newsgroup. The discussions leaders and their e-mail >addresses are listed in the BIOSCI Information Sheet which is >available on the Web at http://www.bio.net/. If a newsgroup is being >hit with too many junk postings, please contact the discussion leader >for that group and see if there is interest in moderating the group. >Please do not assume that by simply posting a complaint to the >newsgroup itself, anyone on the BIOSCI staff will act on your >complaint. With close to 100 newsgroups to run, the BIOSCI staff has >to rely on the discussion leaders of each newsgroup to report problems >directly to us at biosci-help@net.bio.net. > >We will moderate any of our newsgroups if the discussion leader tells >us that the readership of the group wishes to do so and if a moderator >is willing to do the work. For most BIOSCI/bionet groups, this >entails only a few minutes of work each day. > >Moderating a newsgroup will resolve probably 95% of the junk postings >on the USENET distribution. Unfortunately there are easy ways for >determined spammers to override the moderation mechanism on USENET, >but we can protect our e-mail subscribers from unwanted postings if >the newsgroup is moderated. You can also access our newsgroups over >the WWW at URL http://www.bio.net. While this Web interface will not >stop spammers from trying to post to the groups, this will give you >yet another way, besides using USENET news, to keep the junk out of >your personal mail files. For those of you with local USENET news >systems, the Web interface will also give you faster access to new >newsgroups and recent postings. > > >3) Examples of subscribing and unsubscribing to the mailing lists. >------------------------------------------------------------------ >PLEASE NOTE: The BIOSCI management does NOT act on >subscription/unsubscription requests that are posted improperly to the >newsgroups and mailing lists. People who do this only bother everyone >on the lists to no avail. Please be sure to follow the proper >procedures below. > >Gory details are in the BIOSCI Information sheets on the Web at >http://www.bio.net. Below we give an example utilizing the >METHODS-AND-REAGENTS list at both of our two BIOSCI sites: > >Users in the Americas and Pacific Rim countries who use the BIOSCI >------------------------------------------------------------------ >node at computer net.bio.net: >---------------------------- > >A) Determine the "listname" which is the <=8 character mail address > ^^^^^^^^^^^^^ > for the group. These can be found in the BIOSCI Info. Sheet. For > the METHODS-AND-REAGENTS group the mailing address is > methods@net.bio.net. The listname is the portion of the address to > the left of the @ sign, i.e., "methods". The listname is used with > the "subscribe" and "unsubscribe" commands illustrated below. > >B) Mail all commands in the body of a mail message addressed to > biosci-server@net.bio.net. Do NOT send commands to the newsgroup > posting addresses! Leave the Subject: line blank, any text on it > will be ignored. > >C) In the body of your message put one or more of the following > commands with an "end" command on the last line, e.g., > > subscribe methods > unsubscribe methods > end > > Do NOT put your e-mail address or other text on these lines. The > server only allows you to cancel your subscription if the address > on your mail header matches the address on our mailing list. > Please ask for help at biosci-help@net.bio.net if your address has > changed, e.g., if you know you are on the list but the server tells > you that you are not a member. > > >Users in Europe, Africa, and Central Asia who use the BIOSCI node at >-------------------------------------------------------------------- >computer daresbury.ac.uk (also known as dl.ac.uk): >------------------------------------------------- > >To subscribe and unsubscribe to/from the BIOSCI lists, you need to >specify the full USENET newsgroup name with "bionet-news." prepended. >The USENET newsgroup names are listed in the BIOSCI Information sheet >on the Web at http://www.bio.net/. For the METHODS-AND-REAGENTS list >the USENET newsgroup name is bionet.molbio.methds-reagnts, thus the >appropriate commands are > > sub bionet-news.bionet.molbio.methds-reagnts > > unsub bionet-news.bionet.molbio.methds-reagnts > >These commands are included in a message addressed to mxt@dl.ac.uk, >NOT to the newsgroup mailing addresses. As usual, include the text in >the body of the message as text on the Subject: line is ignored. > >To unsubscribe from all the lists at the UK node, use > > unsub bionet-news > >Please note that if the address in the list is different than the one >in your mail message header, you will not be able to unsubscribe by >this method. If you have problems, please mail biosci@daresbury.ac.uk. > > >4) The BIOSCI user address and research interest directory. >----------------------------------------------------------- >Please take this opportunity to add your name, address, and research >interest information to the BIOSCI User Address Database if you have >not already done so. > >You can fill out the address form directly through our Web page at URL >http://www.bio.net/adrform.html. > >The address database is reindexed nightly for WWW access (the URL is >http://www.bio.net/). If you are not directly on the Internet but can >reach it by e-mail, please use our waismail server to access the user >directory. waismail use is described above. You can also request a >user address form by e-mail from biosci-help@net.bio.net. > >Please check your database entry from time-to-time to see if your >address information is still up-to-date. Because of our limited >personnel resources, we ask that you resubmit a *complete* form to >revise your entry; we only replace complete entries and do not have >resources to edit old forms. From owner-schistosoma@net.bio.net Thu Mar 18 22:00:00 1999 Path: biosci!biosci!not-for-mail From: Tom Moreels Newsgroups: bionet.organisms.schistosoma Subject: Schistosomiasis epidemiology Date: 19 Mar 1999 01:10:57 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 16 Sender: daemon@net.bio.net Approved: greveld@uni-duesseldorf.de Distribution: world Message-ID: <7ct4b1$ip4@net.bio.net> NNTP-Posting-Host: net.bio.net Dear, Where can I find a list (to be used as a reference) of the worldwide prevalences of the main parasitic infections (malaria, schistosomiasis...) ? What is the "ranking" of schistosomiasis ? Thank you. Tom Moreels University of Antwerp Universiteitsplein 1 B-2610 Antwerp Tom.Moreels@uia.ua.ac.be